Janux Therapeutics Inc(JANX)
$11.50-0.90 (-7.22%)
JANX
Janux Therapeutics Inc financials statements
$11.50
At close:-0.90 (-7.22%)
Want to see JANX full AI Analyst Report?
Janux Therapeutics Inc (JANX) Ratios
716 Followers
Janux Therapeutics Inc Ratios
JANX's free cash flow for Q3 2026 was $-25.18M. For the 2026 fiscal year, JANX's free cash flow was decreased by $-2.00K and operating cash flow was $-25.18M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 39.04 | 59.21 | 26.80 | 20.14 | 29.46 |
| Quick Ratio | 39.04 | 59.21 | 26.80 | 20.18 | 29.46 |
| Cash Ratio | 2.09 | 24.66 | 1.47 | 3.12 | 2.78 |
| Solvency Ratio | -2.49 | -1.73 | -1.56 | -1.44 | -2.41 |
| Operating Cash Flow Ratio | -3.29 | -2.51 | -3.88 | -2.60 | -1.33 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 931.14M | $ 994.93M | $ 313.18M | $ 289.17M | $ 363.52M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.02 | 0.06 | 0.07 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | 0.02 | 0.07 | 0.08 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 0.02 | 0.07 | 0.07 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.04 | 1.10 | 1.13 | 1.04 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.36 | 0.43 | 0.56 | 0.61 | 0.00 |
| Net Debt to EBITDA | 0.27 | 6.09 | -0.08 | 0.39 | 1.08 |
| Profitability Margins | |||||
| Gross Profit Margin | 79.71% | 80.54% | 75.81% | 90.23% | 100.00% |
| EBIT Margin | -1136.25% | -651.62% | -902.87% | -779.04% | -905.39% |
| EBITDA Margin | -1115.96% | -632.17% | -878.68% | -769.28% | -902.28% |
| Operating Profit Margin | -1576.67% | -933.58% | -902.87% | -779.04% | -905.39% |
| Pretax Profit Margin | -1136.25% | -651.62% | -721.18% | -732.22% | -898.32% |
| Net Profit Margin | -1136.25% | -651.62% | -721.18% | -732.22% | -898.32% |
| Continuous Operations Profit Margin | -1136.25% | -651.62% | -721.18% | -732.22% | -898.32% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 72.07% | 69.80% | 79.88% | 93.99% | 99.22% |
| Return on Assets (ROA) | -11.34% | -6.50% | -15.32% | -17.32% | -8.60% |
| Return on Equity (ROE) | -11.88% | -6.75% | -16.93% | -19.66% | -8.92% |
| Return on Capital Employed (ROCE) | -16.15% | -9.47% | -19.87% | -19.31% | -8.97% |
| Return on Invested Capital (ROIC) | -16.11% | -9.45% | -19.78% | -19.26% | -8.97% |
| Return on Tangible Assets | -11.34% | -6.50% | -15.32% | -17.32% | -8.60% |
| Earnings Yield | -13.29% | -2.40% | -12.34% | -11.55% | -4.02% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.56 | 1.97 | 0.00 | 12.30 | 0.00 |
| Payables Turnover | 0.41 | 0.51 | 0.81 | 0.39 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -1.20 | 0.00 |
| Fixed Asset Turnover | 0.45 | 0.44 | 0.29 | 0.29 | 2.28 |
| Asset Turnover | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 |
| Working Capital Turnover Ratio | 0.01 | 0.02 | 0.02 | 0.03 | 0.02 |
| Cash Conversion Cycle | -659.62 | -527.85 | -452.56 | -1211.16 | 0.00 |
| Days of Sales Outstanding | 234.62 | 185.50 | 0.00 | 29.67 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | -303.80 | 0.00 |
| Days of Payables Outstanding | 894.24 | 713.34 | 452.56 | 937.02 | 0.00 |
| Operating Cycle | 234.62 | 185.50 | 0.00 | -274.14 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.33 | -0.82 | -1.15 | -1.04 | -0.41 |
| Free Cash Flow Per Share | -1.34 | -0.82 | -1.19 | -1.19 | -0.45 |
| Dividend Paid and CapEx Coverage Ratio | -78.84 | -122.04 | -27.34 | -6.66 | -11.45 |
| Capital Expenditure Coverage Ratio | -78.84 | -122.04 | -27.34 | -6.66 | -11.45 |
| Operating Cash Flow Coverage Ratio | -3.71 | -1.90 | -2.06 | -1.70 | -87.51 |
| Operating Cash Flow to Sales Ratio | -8.22 | -4.14 | -6.26 | -4.98 | -4.67 |
| Free Cash Flow Yield | -9.74% | -1.53% | -11.10% | -9.04% | -2.27% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -7.54 | -41.83 | -8.10 | -8.66 | -24.91 |
| Price-to-Sales (P/S) Ratio | 85.51 | 271.80 | 58.43 | 63.42 | 223.74 |
| Price-to-Book (P/B) Ratio | 0.89 | 2.81 | 1.37 | 1.70 | 2.22 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -10.27 | -65.15 | -9.01 | -11.06 | -44.09 |
| Price-to-Operating Cash Flow Ratio | -10.40 | -65.68 | -9.34 | -12.72 | -47.93 |
| Price-to-Earnings Growth (PEG) Ratio | -0.18 | 13.80 | 0.62 | -0.09 | -0.06 |
| Enterprise Value Multiple | -7.39 | -36.91 | -6.72 | -7.85 | -23.72 |
| Enterprise Value | 824.95M | 2.47B | 477.63M | 520.03M | 778.34M |
| EV to EBITDA | -7.39 | -36.91 | -6.72 | -7.85 | -23.72 |
| EV to Sales | 82.49 | 233.31 | 59.09 | 60.38 | 214.01 |
| EV to Free Cash Flow | -9.91 | -55.92 | -9.11 | -10.53 | -42.17 |
| EV to Operating Cash Flow | -10.03 | -56.38 | -9.44 | -12.12 | -45.85 |
| Tangible Book Value Per Share | 15.44 | 19.03 | 7.82 | 7.73 | 8.88 |
| Shareholders’ Equity Per Share | 15.44 | 19.03 | 7.82 | 7.73 | 8.88 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.16 | 0.20 | 0.18 | 0.21 | 0.09 |
| Net Income Per Share | -1.83 | -1.28 | -1.32 | -1.52 | -0.79 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.80 | 0.94 | 0.99 |
| Research & Development to Revenue | 12.59 | 6.46 | 6.79 | 6.21 | 7.21 |
| SG&A to Revenue | 4.18 | 3.88 | 3.23 | 2.58 | 2.84 |
| Stock-Based Compensation to Revenue | 4.02 | 3.12 | 2.47 | 2.00 | 1.90 |
| Income Quality | 0.72 | 0.64 | 0.87 | 0.68 | 0.52 |
Currency in USD
